[Clinical and serological observations of children vaccinated with measles vaccine and those not vaccinated during an epidemic in an inpatient institution].
Explore the source record for details and available documents.
Age Factors↗
SEARCH · PubMed Health
Results for “Measles Vaccine”
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Negative seroconversion and circulating interferon in children vaccinated with live measles vaccine.
In none of the examined children, regardless of whether they manifested negative (17 children) or positive (25 children) seroconversion after vaccination with live measles vaccine, interferon activity could be demonstrated in the serum (starting with 1:4 dilution) withdrawn at the time of the vaccine administration.
Antibodies, Viral↗
Measles vaccination after exposure to natural measles.
When an extensive measles epidemic broke out in Turku in late 1975, the availability of a previous study on measles vaccination reactions in 442 children permitted a comparative evaluation to be made on reactions to and the efficacy of measles vaccine (Schwartz strain) administered after exposure to natural measles. In a preliminary study, nine children were vaccinated one to 14 days after exposure to natural measles but before prodromal symptoms appeared. Only one of these nine children developed symptoms and signs comparable to those of the natural disease. In five day-care centers the children were vaccinated when five or more children out of 30 to 40 at each center had measles. In only five of 74 exposed children were the signs and symptoms comparable to those of natural measles. No marked differences in signs and symptoms after the vaccinations were observed between the exposed and nonexposed children. It is concluded that vaccination is safe, can usually prevent measles, even when administered after a prolonged interval following exposure to natural disease, and can usually control an epidemic in progress.
Adolescent↗
[Several indices of humoral anti-measles immunity in children, previously immunized with live measles vaccine, who have developed measles].
The dynamics of the total content of measles antibody with reference to their physico-chemical nature and the dynamics of the content of the main classes of serum immunoglobulins (A, M, G) in children previously vaccinated and not vaccinated with live measles vaccine who developed measles were studied. Measles in the vaccines was found to run a course of the type of primary and secondary infection. In the former case, the normal dynamics of specific antibody was found with timely change of synthesis of antibody of various physico-chemical nature. In the latter case, immunity to measles developed according to the secondary type and was characterized by the absence of IgM measles antibody. The secondary immunological response was also characterized by higher antibody titers in the first days of the disease and decreased content of IgG and IgM in sera in the convalescent stage. Besides, in such children, hyperthermia occurred 3 times less frequently.
Adolescent↗
Costs and benefits of measles vaccination in Finland.
Measles vaccination is fairly beneficial. During the third year after launching of the vaccination programme, cumulative benefits accuring from vaccination outweigh the cumulative costs of vaccination. This conclusion is based on a study of the vaccination programme in Finland. According to the vaccination programme, all 1-year-old infants in Finland are vaccinated. The duration of the period under survey has been set at 25 years, the measuring unit is the Finnish mark and the price level is that of the year 1975. When comparing costs and benefits, these are converted to present day monetary values. Vaccination costs per vaccinated infant amount to 32 marks, and in total during the period 1975--1999 they will amount to about 34 million marks according to an interest rate of 9% and to about 41 million marks according to an interest rate of 6% in current monetary value. Benefits gained by vaccination, compared with costs, are manifold. The benefits of one vaccination have been estimated at 230 marks. In total, benefits during the period 1975--99 constitute ca 117 million marks at an interest rate of 9%, and ca 159 million marks at an interest rate of 6% in current monetary value, without any deduction for vaccination costs. The net gain of vaccination--with a deduction of vaccination costs--is ca 84 million marks at an interest rate of 9%, and ca 118 million marks at an interest rate of 6% in current monetary value.
Child, Preschool↗
[Materials on the serologic study of children inoculated with live measles vaccine].
The results of serological examination of children, residents of Leningrad, vaccinated with live measles vaccine, are presented. A total of 2012 children were examined. Antibodies were absent in children of different age in 4.2--15.8% of cases. The greatest percentage of secronegative children (15) was noted among those vaccinated at the age of under one year. The mean geometrical antibody titres were the greatest in children aged from 7 to 14 years. The values of these mean titres were less in children vaccinated at the age of under one year than in those vaccinated later--6.5--8.6 and 10.6--11.3, respectively.
Adolescent↗
[Regional conference on measles vaccination. Intervention in discussion].
A short account is given on the reasons for which it is esteemed appropriate the age of 13-15 months suggested by the Regional Consulting Committee as the best period for the extensive voluntary vaccination against measles. At the same time, the practical organization of the campaign can be obstaculated by the miss of sanitary operators.
Adolescent↗
Combination of attenuated measles vaccine (Schwarz) with meningococcus A and A + C vaccine.
There is an obvious interest in a combined meningococcus-measles vaccine since the two diseases are widespread and serious in Third World countries among children under five years of age. The purpose of our study was to show the safety and effectiveness of such a combined preparation. The study covered 110 children between 8 months and 4 years of age who were followed systematically in a maternal child health center in the Paris area. Only 93 of them were checked before and after the immunization. The serologic titrations by the hemagglutination assay (IHA) for measles, and by radioimmunological assay (RIA) for meningococcus A and C showed that the Schwarz strain measles vaccine combined with meningococcus A or the association A+C does not interfere with the increase of A or C titers. 100% of the children showed a seroconversion equal to or less than 2 micrograms per ml, in the case of meningococcus A, as well as for C, regardless of age. Furthermore, 88% of the subjects showed a titer greater than or equal to 4 micrograms for the meningococcus A and 79% for C. On the other hand, meningococcus A or the association A+C seem to depress measles vaccine activity. Nevertheless, more than 80% of the children tested showed seroconversion when the measles vaccine was combined with meningococcus A, and only 69% when combined with meningococcus A and C.
Age Factors↗
[Characteristics of the virus and of measles vaccines (author's transl)].
Characteristics of measles virus and some aspects of virus-cell interaction are reported. For their interest, findings from recents investigations on comparison between SSPE isolates and wild strains are summarized. Both inactivated and live attenuated measles vaccines are then briefly described. The former has been used in the U.S.A. from 1963 to 1968 and discontinued thereafter mainly for safety problems, the latter, prepared with Schwarz or with Moraten strain, are in use today for the prophylaxis against measles.
Animals↗
Evaluation of the eight-year period of compulsory measles vaccination in the Czech Socialist Republic (CSR).
The object of the study is the evaluation of a more than 8-year period of compulsory vaccination against measles in the CSR. So far, a total of 1,850,000 children have been vaccinated. A pronounced decrease has been achieved in morbidity while mortality and lethality reached zero values as early as in 1973. Changes occur in the epidemiological characteristic of measles manifested primarily by the shift of the age distribution of notified cases into older age groups, by continuous prolongation of interepidemic intervals and by gradual disappearances of typical seasonal incidence. Regular immunological surveys have become the most efficient tools in epidemiological surveillance of this infection and in monitoring the vaccination programme. The results of immunological surveys indeed led to the introduction in 1975 of so-called second vaccination compulsory for children starting the first year of school attendance. Up to the present, a total of 24,000 cases of measles have been recorded in children vaccinated earlier, i.e., 1.5% of the total of vaccinated children. It can be expected that measles as a mass disease will be eliminated from the territory of the CSR in the next few years.
Antibodies, Viral↗
Study on the stability of a measles vaccine.
With live measles freeze-dried vaccine, accelerated storage test provides more information than does a titration of residual moisture. From our results, it appears that there is a good correlation between storage at 37 degrees and the tests usually required by the manufacturer, i. e. storage for 1 year at refrigerator temperature. The accelerated test in neither tedious nor expensive and is recommended for routine use.
Drug Stability↗
Neurological complications following measles vaccination.
In Hamburg 18 cases of neurological complications following vaccination with live measles virus vaccine (including 2 cases of abortive encephalopathy) have been observed between 1971--1978. A causal connection was assumed in 14 cases, that means an incidence of 1 neurological complication per 2,500 vaccinees and an incidence of 1 abortive encephalopathy per 17,650 vaccinees. These results differ from studies of various countries which used the same vaccine strain (Schwarz). Clinical symptoms, age distribution and incubation period are demonstrated. The prognosis seems to be good; the risk of vaccination compared to the risk following original measles is between 1:10 (convulsions) and 1:18 (encephalopathy).
Brain Diseases↗
[Costs and benefits of measles vaccination].
Former calculations of the medical benefit of measles immunization, concerning frequency of measles complications, effectiveness and risk of vaccination, showed that measles vaccination is a very useful measure. As the decision to introduce vaccination on a broad scale depends on financial deliberations, too, a cost-benefit analysis for Austria has been performed and the cost-benefit ratio as well as the cost-benefit difference calculated. The costs of measles vaccination which is performed mainly by private pediatricians at the present time, include costs of vaccine, physician and additional antipyretic and is 257.90 AS. The average costs of therapy per child consist of home treatment (287.20 AS), hospital treatment (162.50 AS) and care of residual cerebral damage (88.50 AS). Together with the costs of one week vacation which is warranted in Austria for the nursing of a sick child once a year, this makes a total sum of 1081.--AS. From these data the cost-benefit ratio was calculated by 2.95, the cost-benefit difference by 715.--AS per child. 5 years after the start of general measles vaccination of 1 year old children the accumulated costs of vaccination are equalled by the profit gained by prevention of the disease. The annual cost-benefit difference is positive after 3 years. 10 years after introduction of general vaccination the accumulated cost-benefit difference in Austria would be approximately 167 Mill. AS.
Adolescent↗
Clinical trial of live measles vaccine given alone and live vaccine preceded by killed vaccine. Fourth report to the medical research council by the measles sub-committee of the committee on development of vaccines and immunisation procedures.
Follow-up of 5000 children given a single dose of live attenuated measles vaccine (Schwarz strain) when aged 10 months to 2 years shows a high level of protection in comparison with an unvaccinated group. This protection has been maintained for 12 years. Measles in vaccinated children was less severe as well as less frequent throughout the period. There is no evidence from the follow-up so far that a further injection of vaccine is needed; this has been confirmed by measles haemagglutination-inhibiting antibody estimations in a sample of the children.
Antibodies, Viral↗
[Age of measles vaccination in Lombardy from the results of a seroepidemiological survey in Milan].
In view of the introduction of measles vaccination in Lombardy and since the age of vaccination is of paramount importance, measles h.i.a. were titrated in sera from 209 children between 0 and 6 years of age (of whom 171/0--2) and from 40 woman in the child-bearing age. As it could be expected from the high prevalence of adults with antibody (95%), 90% of umbelical cord sera have h.ia.,, Over 50% of children 15 days-3 months of age are still positive and afterwards the positivity decreases progressivley till a minimum of 8% in children 10--12 months old. Beginning with the second year of life the percentage of immune children grows slowly to reach 50% in the age group 3--6 years. The distribution of antibody titers between 6 and 12 months, time at which maternal antibody are largely waned, suggested that the infection with measles virus is a rare event in the first year of life, while a substantial number of children gets the infection between 18 and 24 months. From these results it appears that also in Lombardy measles vaccination should be given not before 13 months and not after 18 months of age.
Adult↗
Ethiopia missed opportunities for vaccination study: Cluster-randomized evaluation of 5-dose measles vaccine vials and a flexible open-vial policy, 2021-2022.
INTRODUCTION: In 2024, an estimated 95,000 people died from measles globally, largely from suboptimal coverage with the measles-containing vaccine (MCV). Health workers may defer vaccinating eligible children to avoid wasting doses from 10-dose MCV vials, which must be discarded six hours after opening. These missed opportunities for vaccination (MOV) reduce coverage and timeliness. Ethiopia, which provides MCV at 9 and 15 months, considered switching to 5-dose vials. METHODS: We conducted a 15-month, randomized controlled trial with a nested cross-sectional design in Ethiopia. Sixty woredas were randomized to: (1) policy-only, instructing health workers to open 10-dose vials for any number of eligible children, with additional stock for increased wastage; (2) 5-dose switch, combining this policy with replacement of 10-dose by 5-dose vials; or (3) control (routine 10-dose practice). Household and health-facility surveys at baseline and endline assessed effects on first-dose (MCV1) and second-dose (MCV2) coverage, MCV1 timeliness, and wastage. Generalized estimating equation models estimated net intervention effects versus control. We also estimated the government cost of a nationwide 5-dose switch. RESULTS: MCV1 coverage was similar between policy-only and control (adjusted risk difference [ARD] = -1%, 95%CI: -17%, 15%), with no significant differences in MCV1 timeliness or MCV2 coverage. In the 5-dose switch group, MCV1 coverage changed little (ARD = 1%, 95%CI: -17%, 18%), but timely MCV1 at 9 months (ARD = 18%, 95%CI: 7%, 28%) and MCV2 coverage (ARD = 17%, 95%CI: 1%, 34%) rose significantly, and wastage fell (ARD = -7%, 95%CI: -14%, -1%). By endline, 29% of 5-dose health workers opened vials ≥10 times monthly (none in control); caregivers in both intervention groups reported 11% fewer measles-related MOVs. A nationwide 5-dose switch was estimated to save 17% in procurement cost per fully vaccinated (two-dose) child. CONCLUSIONS: The combined 5-dose intervention improved MCV1 timeliness and MCV2 coverage and reduced wastage, addressing a key operational barrier and potentially supporting measles elimination in Ethiopia.
Humans↗
[Effect of a live measles vaccine on the chromosome apparatus of mouse bone marrow cells].
Vaccination of albino mice with live measles vaccine caused an increase in the chromosome aberrations frequency during the period from the 30th till the 120th day of the experiment. The maximum increase in the number of chromosome aberrations as well as in centromeric and telomeric chromosome associations was observed 60 days after immunization. Chromatid breaks were main type of the structural aberrations observed.
Animals↗
[A controlled experience with a thermostabile measles vaccine in Cameroon (author's transl)].
Rimevax, a thermostabile measles vaccine, has been stored, before reconstitution, during seven days at temperature from 23 degrees C to 25 degrees C. This vaccine has given seroconversion in 87 per 100 of the babies vaccinated and aged from 9 to 24 months. This percentage assesses the value of Rimevax for field campaigns.
Age Factors↗